Emmessar Biotech & Nutrition Ltd. ಖಾತೆಯ ಉಪಯುಕ್ತ ಮಾಹಿತಿ

Mar 31, 2025

xvii) Provisions, Contingent Liabilities and Contingent Assets

Provision is recognized only when the Company has a present obligation as a result of past event and it is probable that an outflow of resources
will be required to settle the obligation in the respect of which a reliable estimate can be made based on technical evaluation and past
experience. Provisions are not discounted to its present value and are determined based on management estimate required to settle the
obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.

xviii) Fair Value measurement

a) The Company measures financial instruments i.e. derivative contracts at fair value at each balance sheet date.

b) Fair value is the price that would be received on selling an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at
that date.

c) While measuring the fair value of an asset or liability, the Company uses valuation techniques that are appropriate in the circumstances and
for which sufficient data are available to measure the fair value using observable market data as far as possible and minimising the use of
unobservable inputs. Fair values are categorised into 3 levels as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2:inputs other than quoted prices that are observable for the assets or liability, either directly (i.e. as prices for similar item) or indirectly (i.e.
derived from prices)

Level 3: inputs that are not based on observable market data (unobservable inputs)

xix) Financial Instruments

I. Financial Assets other than derivatives

All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss
(FVTPL), transaction costs that are attributable to the acquisition of the financial asset. However, trade receivables that do not contain a
significant financing component are measured at transaction price.

A financial asset is measured (subsequent measurement) at the amortised cost if the asset is held within a business model whose objective
is to hold assets for collecting contractual cash flows, and the contractual terms of the asset give rise on specified dates to cash flows that are
solely payments of principal and interest on the principal amount outstanding.

Amortised cost is net of any write down for impairment loss (if any) using the effective interest rate (EIR) method taking into account any
discount or premium and fees or costs that are an integral part of the EIR.

A financial asset is derecognised either partly or fully to the extent the rights to receive cash flows from the asset have expired and / or the
control on the asset has been transferred to a third party. On de-recognition, any gains or losses are recognised in the Statement of Profit &
Loss.

ii. Financial Liabilities other than derivatives

All financial liabilities are recognised initially at fair value net of transaction costs that are attributable to the respective liabilities.

After initial recognition, financial liabilities are subsequently measured at amortised cost using the effective interest rate method (“EIR”).
Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the
EIR. The EIR amortisation is included as finance costs in the Statement of Profit & Loss.

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial
liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially
modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The
difference in the respective carrying amounts is recognised in the Statement of Profit & Loss.

iii. Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable
legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities
simultaneously.

xx) Classification of Assets and Liabilities as Current and Non-Current:

All assets and liabilities are classified as current if they are expected to be realised / settled within twelve months after the reporting period.
All other assets and liabilities are considered as non-current.

D. Other Long Term Benefits

The Company does not have any other Long Term benefits

37 : Accounting Standard (Ind AS) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare,Fine Chemicals and
Rent on Immovable property. Revenues and expenses directly attributable to segments are reported under each reportable segment.
Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the
segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses.
Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and
liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

(ii) The management assessed that the fair values of cash and cash equivalents, other bank balances, trade receivables, loans, other financial
assets, borrowings, trade payables, and other financial liabilities approximates their carrying amounts largely due to the short-term maturities of
these instruments.

(iii) Fair value of non current other financial assets approximates their carrying amount due to no change in redemption value.

(iv) For Financial assets and liabilities that are measured at fair value, the carrying amounts are equal to their fair values.

(v) The fair value of the financial assets and financial liabilities is included at the amount at which the instruments could be exchanged in a current
transaction between willing parties, other than in a forced or liquidation sale.

(vi) The following methods and assumptions were used to estimate the fair values:aThe Equity Investments which are Quoted, the fair value has
been taken at the market prices/ NAV of the same as on the reporting dates. They are classified as Level 1 fair values in fair value hierarchy.bThe
derivative financial instruments which are unquoted, the fair value has been taken at based on value certificate given by respective Banks.
They are classified as Level 2 fair values in fair value hierarchy.cThe Equity Investments which are Unquoted, the fair value has been taken as
per the valuation report certified by Chartered Accountant as on the reporting dates. They are classified as Level 3 fair values in fair value
hierarchy.

(vii) Fair Value Hierarchy

A The following are the judgements and estimates made in determining the fair values of the financial instruments that are

(a) recognized and measured at fair value and

(b) measured at amortized cost and for which fair value are disclosed in the financial statements. To provide an indication about the reliability of
the inputs used in determining fair value, the company has classified its financial instruments into the three levels of fair value measurement as
prescribed under the Ind AS 113 "Fair Value Measurement". An explanation of each level follows underneath the tables.

a Assets and Liabilities measured at Fair Value.

51: OTHER DISCLOSURE UNDER SCHEDULE-III

1. No funds have been advanced or loaned or invested by the company to or in any other persons or entities, including foreign entities
(Intermediaries) with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend
or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or provide any
guarantee, security or the like on behalf of the Ultimate Beneficiaries.

2. No funds have been received by the compay from any persons or entities, including foreign entities (Funding Parties) with the understanding,
whether recorded in writing or othersise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified
in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of
the Ultimate Beneficiaries.

3. The company does not have any contingent liabilities as on 31st March 2025

4. The Company does not have any long-term contracts including derivative contracts for which there are any material forseable losses.

5. No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions
(Prohibition) Act, 1988 (45 of 1988).

6. The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender.

7. During the year, the company has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013 or
section 560 of Companies Act, 1956.

8. There are no transactions which have not been recorded in the books of accounts and which have been surrendered or disclosed as income
during the year in the tax assessments under the Income Tax Act, 1961.

9. A charge of INR 1,10,00,000/- created on 16.12.1994, remains unsatisfied despite the debt has been repaid.

10. The company does not have layers beyond the number prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on
number of Layers) Rules, 2017.

11. The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

52: Recent Pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting
Standards) Rules as issued from time to time. On March 31,2023, MCA amended the Companies (Indian Accounting Standards) Amendment
Rules, 2023, as below:

Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than
their significant accounting policies. The effective date for adoption of this amendment is annual periods beginning on or after April 1,2023. The
Company has evaluated the amendment and the impact of the amendment is insignificant in the standalone financial statements.

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of ‘accounting
estimates’ and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting
estimates.

The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the
amendment and there is no impact on its standalone financial statements.

Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions
that give rise to equal and offsetting temporary differences. The effective date for adoption of this amendment is annual periods beginning on or
after April 1,2023. The Company has evaluated the amendment and there is no impact on its standalone financial statement.

53 : Previous year figures re-grouped / re-classified where ever necessary

As Per Our Report of Even Date attached

For V Nagarajan & Co For and on behalf of the Board

Chartered Accountants

Firm Regn No. 004879N Srinivasa Raghavan Jeyavel B. Nadar

Mathurakavi Ayyangar Executive Director & CFO

Managing Director DIN: 08163899

DIN: 00090266

Shankar Cherukupally Priyanka O. Sharma

Partner Company Secretary

M.No 252304 M. No. A52518

Place : Hyderabad Place: Mumbai

Date : 24th April 2025 Date: 24th April 2025

---

Mar 31, 2024

b) The Company has not declared any Dividend.

c) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders

d) List of Shareholders holding more than 5% of the Total Number of Shares issued by the Company

34 : Commitments & Contingent Liabilities		(? in Lakhs]
Particulars	Year Ended	Year Ended
	31.03.2024	31.03.2023
a) Estimated Amount of Contract remains to be executed and not provided for in the accounts	NIL	NIL
b) Claims against the Company not acknowledges as Debts	NIL	NIL

The estimation of future salary increases considered in Acturial Valuation takes account of infaltion, seniority promotions, and other relevant factor on long term basis

D. Other Long Term Benefits

The Company does not have any other Long Term benefits

36 : Accounting Standard (Ind AS) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare,Fine Chemicals and Rent on Immovable property. Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

38 : Due to/ from parties are subject to confirmation

39 : In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business

which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

40 : As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign

currency to its non resident shareholders during the current year as well as previous year.

Deferred Tax Asset on unabsorbed depreciation and other temporary differences available as per the Income Tax Act, 1961 has been recognized, since it is probable that taxable profit will be available to adjust them in future years. Unabsorbed depreciation which forms a major portion of the Deferred Tax Asset can be carried forward and set off against profits for unlimited number of years under the Indian Income Tax Act, 1961; and profitability projections based on current refining margins show sufficient profits for set-off in future.

49 : OTHER DISCLOSURE UNDER SCHEDULE-III

1. No funds have been advanced or loaned or invested by the company to or in any other persons or entities, including foreign entities (Intermediaries) with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

2. No funds have been received by the company from any persons or entities, including foreign entities (Funding Parties) with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

3. The company does not have any contingent liabilities as on 31st March 2024

4. The Company does not have any long-term contracts including derivative contracts for which there are any material forseable losses.

5. No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988).

6. The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender.

7. During the year, the company has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

8. There are no transactions which have not been recorded in the books of accounts and which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

9. A charge of INR 1,10,00,000/- created on 16.12.1994, remains unsatisfied despite the debt has been repaid.

10. The company does not have layers beyond the number prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017.

11. The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

50 : Recent Pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 31,2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023, as below:

Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than their significant accounting policies. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and the impact of the amendment is insignificant in the standalone financial statements.

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of ‘accounting estimates’ and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting estimates. The effective date for adoption of this amendment is annual periods beginning on or after April 1,2023. The Company has evaluated the amendment and there is no impact on its standalone financial statements.

Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences. The effective date for adoption of this amendment is annual periods beginning on or after April 1,2023. The Company has evaluated the amendment and there is no impact on its standalone financial statement.

51 : Previous year figures re-grouped / re-classified where ever necessary

---

Mar 31, 2015

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar

1.3 Due to/ from parties are subject to confirmation.

1.4 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.5 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.6 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.7 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure

---

Mar 31, 2014

Particulars

Year Ended31.3.2014 Year Ended 31.3.2013

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits The Company''s does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

Particulars - for the year ended March 31, 2014

1.3 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar Details of the transactions with above parties

Financial transactions have been carried out in the ordinary course of business and/ or in discharge of contractual obligations

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.7 Value of Imports on CIF Basis

1.8 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.9 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure

---

Mar 31, 2013

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallowable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are disclosed as unallowable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emissary Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) A.V.Vardharajan - Executive Director ( Worked up to January 2013)

iii) A.V. Saranagaranjan - Brother of A.V. Vardharanjan( Worked up to October 2012)

iv) Vasudevan Raghavan - Son of MSR Ayyangar (Worked up to August 2012)

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognized, as there is uncertainty of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realizable at value stated in ordinary course of business which are at least equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its nonresident shareholders during the current year as well as previous year.

---

Mar 31, 2012

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts (Net of Payments Made) in respect of Capital Assets NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits

The Company's does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.AII other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognised, as there is uncertanity of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year.

1.7 The Revised Schedule VI has become effective from 1st April 2011 for the preparation of financial statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous Years figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification/ disclosure.

---

Mar 31, 2010

1. a) Contingent Liabilities: NIL

b) Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advances) : NIL

2. Registration is pending for 2 residential flats included in buildings shown in the Schedule III of Fixed Assets.

3. The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business losses from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof, no Provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However, Deferred Tax Asset has not been recognised, as there is uncertainty of the realization thereof in the future.

4. Sundry Debtors include Rs.5.82 lakhs due from customers outstanding for a considerable long period. During the year the company has recovered Rs. 1.23 Lacs from these customers. In the opinion of the management the entire amount is recoverable and hence considered good.

5. Quantitative information as required by paragraph 3 of Part II of Schedule VI to the Companies Act, 1956 (As Certified by the Management):

a) LICENSED AND INSTALLED CAPACITY - NIL b) PRODUCTION

The aforesaid remuneration does not exceed Rs. 100000/ per month or Rs. 1200000/- per annum (the effective capital of the Company is Rs. 1 Crore or more but less than Rs. 5 Crores) as provided in Part II of Schedule XIII to the Companies Act, 1956 vide Circular No. GSR 36(E) issued in connection with Remuneration Payable by the Companies having no profits or inadequate profits as payment of remuneration is approved by a resolution passed by the members in the General Meeting of the Company and the Company has not made any default in repayment of any of its debts or interest payable thereon.

6. EARNING PER SHARE

The Numerator and Denominator used to calculate Basic / Diluted Earning Per Share and the Calculated Basic / Diluted Earning Per Share is as under.

7. RELATED PARTY DISCLOSURES: List of related parties.

a) Parties where control exists — None b) Other related parties with whom transactions have taken place during the year:

i) Emmessar Technologies Limited.

c) Key Management Personnel and their Relatives

i) MSR Ayyangar (Managing Director)

ii) A.V. Vardharajan (Executive Director)

iii) A.V. Sarangarajan(Brother of A.V. Vardharajan)

iv) Vasudevan Raghavan (Son of MSR Ayyangar)

Details of remuneration to Managing Director & Executive Director are disclosed at Note No. 14 herein before.

8. In the opinion of the Management, the Current Assets, Loans and Advances are expected to produce at least equal to the amount at which they are stated in the Balance Sheet in the ordinary course of business.

9. Dues to/ from parties are subject to confirmation.

10. As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non- resident shareholders during the current year as well as previous year.

11. In the opinion of the Management, the provisions for all known undisputed liabilities are adequate and is neither in excess nor short of the amount reasonably considered necessary.

12. There is no amount due to "Micro or Small Enterprises" and Medium Enterprises Act, 2006. Further no interest is paid / payable in terms of section 16 of the said Act. The information regarding dues to "Micro or Small Enterprises" are given to the extent such parties have been identified on the basis of information available with the Company.

13. Additional information pursuant to the provision of Part IV of Schedule VI to the Companies Act, 1956, pertaining to Balance Sheet Abstract and Companys General Business Profit is annexed hereto.

14. Schedules "I" to "XI" form integral part of the accounts and have been duly authenticated.

15. Previous year figures have been reclassified / regrouped / recasted / rearranged wherever considered necessary to conform with the classification of the current year and to make them comparable with the current years figures.